Lona Poole
FibroGen (United States)(US)
Publications by Year
Research Areas
Erythropoietin and Anemia Treatment, Sepsis Diagnosis and Treatment, Iron Metabolism and Disorders, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Hemoglobinopathies and Related Disorders
Most-Cited Works
- → Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis(2003)953 cited
- Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.(1998)
- → Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock(1998)501 cited
- → Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study(2016)254 cited
- → Roxadustat (FG-4592)(2015)246 cited
- → Roxadustat for anemia in patients with end-stage renal disease incident to dialysis(2021)121 cited
- → Pamrevlumab for Idiopathic Pulmonary Fibrosis(2024)49 cited
- → A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia(2009)45 cited
- → The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol(2010)39 cited
- → Pamrevlumab for Idiopathic Pulmonary Fibrosis: Results of the Phase 3 Zephyrus-1 Study(2024)4 cited